MediPharm Labs Signs New Cannabis Oil Agreements and Completes First Shipments of Supply in December

TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSXV: LABS; OTCQB: MLCPF) (the “Company” or “MediPharm Labs”), the leader in specialized, research-driven cannabis extraction, fully licensed under the Cannabis Act (Canada) focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification, is pleased to announce it has signed three cannabis oil sales agreements, subsequent to the Company’s receipt of its sales license from Health Canada on November 9, 2018.  The first large shipments of cannabis oil supply left the Company’s dock in December 2018 and were aggregately valued at over $10 million.

“As a pioneer in the cannabis industry, MediPharm Labs has emerged as the clear leader in the extraction-only category, highlighted by our first month of sales agreements of white label high-quality purified cannabis oil concentrates,” said Mr. Patrick McCutcheon, Chairman, President and Chief Executive Officer of MediPharm Labs. “This milestone further validates the

... read more at: